Seminoma Clinical Trial
— THERATESTOfficial title:
THERApy De-escalation for TESTicular Cancer
NCT number | NCT06309745 |
Other study ID # | THERATEST |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 25, 2024 |
Est. completion date | December 2027 |
THERATEST is looking to collect data from 30 patients actively receiving de-escalation treatments or other standard of care treatments in two UK hospitals. THERATEST is a feasibility study to determine whether patients are willing to be recruited, the impact of de-escalation treatments on patients' cancers and quality of life, whether we should proceed with these treatments in a larger study, and if so how the study should be conducted. A feasibility study prepares the ground for a larger study and improves the chances of the subsequent study producing valuable evidence, and helps to avoid wasting precious resources on larger trials that are unlikely to be informative. We hope that information from THERATEST will bridge the current knowledge gap and allow clinicians to design bigger trials to actively compare the different treatment strategies.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 2027 |
Est. primary completion date | May 2027 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: Each patient must meet all of the following inclusion criteria to be enrolled in the study: 1. Willing and able to provide written informed consent. 2. Male. 3. Age = 16 years. 4. Histologically confirmed seminoma (biopsy/orchidectomy) 5. Clinical stage II (standard of care cross-sectional imaging). 6. Ability to comply with the protocol, including but not limited to, completion of the patient-reported outcome questionnaires. rRPLND cohort specific inclusion criteria Participants must meet the following additional inclusion criteria to register for the rRPLND cohort: 1. Stage IIA and <3cm IIB with unifocal ipsilateral lymph node within rRPLND template. 2. Negative or mildly elevated serum tumour markers, defined as: 1. AFP (alpha-fetoprotein) <10ng/ml and non-rising on serial testing 2. BhCG (human chorionic gonadotropin) <50mg/ml 3. LDH (lactate dehydrogenase) <1.5x upper limit normal 3. Fit for surgery, defined as meeting all of the following criteria: 1. Body mass index (BMI) <34 2. Charlson comorbidity index =3 3. ECOG Performance status 0-1 4. No significant cardio-pulmonary disease, or other uncontrolled intercurrent illness that would limit fitness for surgery in the opinion of the investigator 5. No previous open intra-abdominal surgery Carboplatin AUC10 cohort specific inclusion criteria Participants must meet the following additional inclusion criteria to register for the Carboplatin AUC10 group: 1. Serum tumour markers, defined by IGCCCG "good risk" criteria: 1. AFP <10ng/ml 2. any BhCG 3. LDH <2.5x ULN 2. Glomerular filtration rate by EDTA clearance over 25 ml/min (a measured creatinine clearance using Cockcroft and Gault would be allowed if unable to perform EDTA clearance). 3. ECOG Performance status 0-2. 4. Patients must be sterile or agree to use adequate contraception during the period of therapy. Exclusion Criteria: 1. Raised AFP > 10ng/ml that does not fall to <10ng/ml following orchidectomy 2. Previous chemotherapy or radiotherapy for the disease under study. 3. Previous or concurrent malignancy other than testicular cancer, unless treated with curative intent and with no known active disease present for =2 years before enrolment and felt to be at low risk for recurrence by the treating physician (for example: non-melanoma skin cancer or lentigo maligna; breast ductal carcinoma in situ; prostatic intraepithelial neoplasia; urothelial papillary non-invasive carcinoma or urothelial carcinoma in situ). 4. Any condition that, in the opinion of the investigator, would interfere with evaluation of study intervention or interpretation of patient safety or study results such as medical comorbidities impacting on QoL or medical conditions or other disorders that would affect adherence to study requirements |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Barts and London Hospital NHS Trust | London |
Lead Sponsor | Collaborator |
---|---|
Queen Mary University of London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | FEASIBILITY of recruitment and retention | To demonstrate feasibility of recruitment and retention (number of participants recruited per month and retained annually). Completion of recruitment of 30 patients into the THERATEST study, and measurement of overall patient retention within the trial until the 2-year follow-up visit. | through study completion, an average of 3 year | |
Secondary | QUALITY OF LIFE assessed by difference in HRQOL scores | To determine differences in Health-related QOL (HRQOL) before and after treatment(s). Change in domain scale scores/single item scores in European Organisation for Research and Treatment of Cancer (EORTC) QLQ-TC26 and EORTC QLQ-C30, measured from baseline until the 2-year follow-up visit. | through study completion, an average of 3 year | |
Secondary | QUALITY OF LIFE assessed by difference in differences in sexual drive, function, and overall satisfaction | To determine differences in sexual drive, function, and overall satisfaction before and after treatment(s). Change in domain scale scores/single item scores in Brief Male Sexual Function Inventory (BMSFI), QLQ-TC26, and supplementary questions on retrograde ejaculation. Measured from baseline until the 2-year follow-up visit. | through study completion, an average of 3 year | |
Secondary | Progression free SURVIVAL | • To determine progression-free survival (PFS) and overall survival (OS) rates ensuring these fall in line with standard of care treatments outcomes (>95%). PFS rate at 2 years, defined as the proportion of patients who did not experience disease progression or death from any cause during the 2-year follow-up period. | through study completion, an average of 3 year | |
Secondary | OVERALL SURVIVAL | • To determine progression-free survival (PFS) and overall survival (OS) rates ensuring these fall in line with standard of care treatments outcomes (>95%). OS rate at 2 years, defined as the proportion of patients who did not experience death from any cause during the 2-year follow-up period. | through study completion, an average of 3 year | |
Secondary | SAFETY and complication of all treatments | • To assess the safety and complications of all treatments. Incidence, nature and severity of adverse events with severity determined according to CTCAE v5.0 collected from consent until 6 weeks post-surgery or chemotherapy.
Surgical complications will be assessed by the Clavien-Dindo scoring system, and analysing details of surgical complications, blood transfusion, ITU admission and dialysis rates from patient records up to 6 months post-rRPLND. |
through study completion, an average of 3 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06133543 -
Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer
|
N/A | |
Recruiting |
NCT05529251 -
De-escalation Study for Stage IIa/IIb < 3 cm Seminoma
|
Phase 2 | |
Completed |
NCT00705094 -
Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients
|
N/A | |
Active, not recruiting |
NCT03158064 -
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
|
Phase 2 | |
Recruiting |
NCT01887340 -
Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma
|
Phase 2 | |
Active, not recruiting |
NCT01593241 -
Therapy De-escalation in Seminoma Stage IIA/B
|
Phase 2 | |
Recruiting |
NCT04876456 -
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
|
Phase 2 | |
Active, not recruiting |
NCT03937843 -
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
|
Phase 2 | |
Recruiting |
NCT04435756 -
A Study of miRNA 371 in Patients With Germ Cell Tumors
|
||
Active, not recruiting |
NCT02834013 -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
|
Phase 2 | |
Recruiting |
NCT04914026 -
MicroRNA as Markers in Testicular Cancer
|
||
Not yet recruiting |
NCT05142982 -
Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma
|
N/A | |
Active, not recruiting |
NCT02375204 -
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
|
Phase 3 | |
Recruiting |
NCT06144736 -
PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND
|
Phase 2 | |
Recruiting |
NCT02341989 -
Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer
|
Phase 3 |